A method for applying ultrasound to activate a cavitation enhancing agent in the presence of a therapeutic compound and a microbial biofilm is provided. The ultrasound energy causes the cavitation enhancing agent to cavitate in the ultrasound field. The cavitation of the resultant bubble causes fluid streaming and shear forces at and near the biofilm, causing enhanced penetration of the therapeutic compound into the biofilm, and resulting in improved efficacy of the therapeutic compound against the biofilm. The method further includes cavitation enhancing agents which can be loaded with oxygen gas or combined with microbubbles which carry oxygen gas, which further potentiate antibiotic efficacy against the biofilm.

Provided herein is a method of extending the lifespan of an organism comprising administering to the organism an effective amount of a ferroptosis inhibitor. Also provided are compositions for extending lifespan comprising ferroptosis inhibitors.

Provided herein is a method of extending the lifespan of an organism comprising administering to the organism an effective amount of a ferroptosis inhibitor. Also provided are compositions for extending lifespan comprising ferroptosis inhibitors.

Compounds that inhibit activation of Discoidin Domain Receptor 2 (DDR2) and methods of using the compounds to inhibit DDR2 activation, inhibit migration of cells expressing DDR2, and treat diseases or disorders associated with DDR2 dysfunction.

Compounds that inhibit activation of Discoidin Domain Receptor 2 (DDR2) and methods of using the compounds to inhibit DDR2 activation, inhibit migration of cells expressing DDR2, and treat diseases or disorders associated with DDR2 dysfunction.

Provided herein are spirocycle compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful as modulators of MAGL and/or ABHD6. Furthermore, the subject compounds and compositions are useful for the treatment of pain.

The invention relates to compounds useful for inhibiting at least one member of the BET family and at least one kinase such as but not limited to mTOR, and to methods of treating diseases including COVID-19 by administration of a compound(s) of Formulas I-V or pharmaceutically acceptable salts thereof as defined herein.

The invention relates to compounds useful for inhibiting at least one member of the BET family and at least one kinase such as but not limited to mTOR, and to methods of treating diseases including COVID-19 by administration of a compound(s) of Formulas I-V or pharmaceutically acceptable salts thereof as defined herein.

The invention relates to compounds useful for inhibiting at least one member of the BET family and at least one kinase such as but not limited to mTOR, and to methods of treating diseases including COVID-19 by administration of a compound(s) of Formulas I-V or pharmaceutically acceptable salts thereof as defined herein.

The present invention relates to a combination product and its use in therapy.